Crossmark Global Holdings Inc. Has $7.11 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Crossmark Global Holdings Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 16.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,150 shares of the company's stock after purchasing an additional 6,214 shares during the period. Crossmark Global Holdings Inc.'s holdings in Zoetis were worth $7,105,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its position in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in Zoetis by 5.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock valued at $68,354,000 after purchasing an additional 21,470 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in Zoetis by 61.0% in the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock valued at $497,000 after purchasing an additional 1,157 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Zoetis by 5.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 217,094 shares of the company's stock valued at $35,371,000 after purchasing an additional 12,174 shares during the last quarter. Finally, Isthmus Partners LLC lifted its stake in Zoetis by 0.3% in the 4th quarter. Isthmus Partners LLC now owns 68,821 shares of the company's stock valued at $11,213,000 after purchasing an additional 173 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is currently owned by company insiders.

Zoetis Trading Down 2.4%

NYSE ZTS traded down $3.89 on Friday, hitting $154.91. The company's stock had a trading volume of 2,267,443 shares, compared to its average volume of 2,591,358. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company's 50-day moving average is $161.32 and its 200 day moving average is $161.86. The firm has a market cap of $68.97 billion, a PE ratio of 27.81, a PEG ratio of 2.63 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the prior year, the company posted $1.38 EPS. The company's revenue was up 1.4% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.29%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Analyst Ratings Changes

Several equities analysts recently commented on ZTS shares. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.